Publicacions en què col·labora amb José Ángel García Pedraza (23)

2024

  1. Chronic sarpogrelate treatment improves renal sympathetic hyperactivity in experimental diabetes

    Biomedicine and Pharmacotherapy, Vol. 176

2023

  1. Fármacos que actúan modulando la actividad enzimática

    Fundamentos de farmacología básica y clínica (Editorial Médica Panamericana), pp. 101-112

  2. Renal Sympathetic Hyperactivity in Diabetes Is Modulated by 5-HT1D Receptor Activation via NO Pathway

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

2022

  1. Effect of sarpogrelate treatment on 5-HT modulation of vascular sympathetic innervation and platelet activity in diabetic rats

    Biomedicine and Pharmacotherapy, Vol. 153

  2. Fluoxetine Treatment Decreases Cardiac Vagal Input and Alters the Serotonergic Modulation of the Parasympathetic Outflow in Diabetic Rats

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  3. Oral fluoxetine treatment changes serotonergic sympatho-regulation in experimental type 1 diabetes

    Life Sciences, Vol. 293

2021

  1. Vascular sympathetic neurotransmission and its serotonergic regulation are modified by chronic fluoxetine treatment

    Journal of Pharmacological Sciences, Vol. 147, Núm. 1, pp. 48-57

2020

  1. Blockade of 5-HT2 receptors with sarpogrelate uncovers 5-HT7 receptors inhibiting the tachycardic sympathetic drive in pithed rats

    Clinical and Experimental Pharmacology and Physiology, Vol. 47, Núm. 3, pp. 403-411

  2. Dopamine D4 receptor subtype activation reduces the rat cardiac parasympathetic discharge

    Pflugers Archiv European Journal of Physiology, Vol. 472, Núm. 12, pp. 1693-1703

  3. Role of peripheral 5-HT5A receptors in 5-HT-induced cardiac sympatho-inhibition in type 1 diabetic rats

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Fluoxetine oral treatment discloses 5-HT 1D receptor as vagoinhibitor of the cardiac cholinergic neurotransmission in rat

    Canadian Journal of Physiology and Pharmacology, Vol. 97, Núm. 2, pp. 90-98

  2. Hypertension exhibits 5-HT 4 receptor as a modulator of sympathetic neurotransmission in the rat mesenteric vasculature

    Hypertension Research, Vol. 42, Núm. 5, pp. 618-627

2018

  1. Chronic 5-HT2 receptor blockade unmasks the role of 5-HT1F receptors in the inhibition of rat cardioaccelerator sympathetic outflow

    Canadian Journal of Physiology and Pharmacology, Vol. 96, Núm. 4, pp. 328-336

2017

  1. 5-HT modulates the rat mesenteric vasopressor outflow by 5-HT1D sympatholytic receptors

    Clinical and Experimental Pharmacology and Physiology, Vol. 44, Núm. 12, pp. 1224-1231

  2. Chronic Sarpogrelate Treatment Reveals 5-HT7 Receptor in the Serotonergic Inhibition of the Rat Vagal Bradycardia

    Journal of Cardiovascular Pharmacology, Vol. 69, Núm. 1, pp. 13-22

2016

  1. 5-HT2 receptor blockade exhibits 5-HT vasodilator effects via nitric oxide, prostacyclin and ATP-sensitive potassium channels in rat renal vasculature

    Vascular Pharmacology, Vol. 79, pp. 51-59

  2. Blocking 5-HT2 receptor restores cardiovascular disorders in type 1 experimental diabetes

    Scientific Reports, Vol. 6

  3. Pharmacological Evidence that Histamine H3 Receptors Mediate Histamine-Induced Inhibition of the Vagal Bradycardic Out-flow in Pithed Rats

    Basic and Clinical Pharmacology and Toxicology, Vol. 118, Núm. 2, pp. 113-121

2015

  1. 5-HT1D receptor inhibits renal sympathetic neurotransmission by nitric oxide pathway in anesthetized rats

    Vascular Pharmacology, Vol. 72, pp. 172-180

  2. Pharmacological evidence that 5-HT1D activation induces renal vasodilation by NO pathway in rats

    Clinical and Experimental Pharmacology and Physiology, Vol. 42, Núm. 6, pp. 640-647